OMEROS CORP
No enriched coverage for $OMER in the last 7 days.
No SEC Form 4 filings for $OMER in the last 30 days.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 5,961,792 shares of Omeros Corp common stock, or 8.2% of the outstanding class. The filing shows sole voting power over 5,835,368 shares and sole dispositive power over 5,961,792 shares, with no shared voting or dispositive power.
Biotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.
Omeros (NASDAQ:OMER) said the EMA’s CHMP adopted a negative opinion on its marketing authorization application for narsoplimab, an antibody targeting MASP-2 for transplant-related thrombotic microangiopathy. Omeros plans to request reconsideration and an Ad Hoc Expert Panel review. H.C. Wainwright cut its price target to $33 from $40, keeping a Buy rating.
Recent OMER coverage spans financial news, market movers and regulation.
The filing signals a large, sole-voting and sole-dispositive holder presence, which can affect perceived shareholder influence but does not disclose operational changes.
Competitive setback for Ultomiris reduces near-term threat to Omeros’ YARTEMLEA, supporting bullish read-through.
Regulatory setback in the EU process, but management is pursuing reconsideration, keeping a path to eventual approval.
Routine but concrete governance outcomes (board elections, say-on-pay, equity plan, auditor ratification) that can reduce uncertainty around corporate governance.
The disclosed early commercial revenue and profitability drivers are the main incremental facts for OMER.
alphai scores every news story that mentions OMER with an AI model for sentiment and relevance, and aggregates insider trades from OMEROS CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 5,961,792 shares of Omeros Corp common stock, or 8.2% of the outstanding class. The filing shows sole voting power over 5,835,368 shares and sole dispositive power over 5,961,792 shares, with no shared voting or dispositive power.
3 min readBiotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.
6 min readOmeros (NASDAQ:OMER) said the EMA’s CHMP adopted a negative opinion on its marketing authorization application for narsoplimab, an antibody targeting MASP-2 for transplant-related thrombotic microangiopathy. Omeros plans to request reconsideration and an Ad Hoc Expert Panel review. H.C. Wainwright cut its price target to $33 from $40, keeping a Buy rating.
4 min readOMEROS CORP (OMER) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. omer20260613_8k.htm false 0001285819 0001285819 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
2 min readThe article compares NovoCure and Omeros on valuation and growth prospects. NovoCure received FDA approval for Optune Pax for advanced localized pancreatic cancer, and it projects $704 million revenue for 2026, with no free cash flow expected until fiscal 2028. Omeros reported $9.89 million Q1 2026 Yartemlea sales and $56.06 million net income from Novo Nordisk upfront payments, with analysts forecasting about $68 million revenue in 2026.
6 min readOmeros Corp (Nasdaq: OMER) shares surged 75.5% after the US FDA approved its drug Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Yartemlea is the first and only approved lectin pathway inhibitor for this often-fatal complication. The global market for complement-mediated thrombotic microangiopathy therapies reached $2.14 billion in 2024 and is projected to grow with a CAGR of 10.7%.
3 min readOmeros (OMER) stock is seeing significant retail attention ahead of an FDA decision on its drug Narsoplimab, a treatment for post-stem cell and bone marrow transplant complications, which is due on December 26, 2025. Stocktwits users are "extremely bullish" with high message volumes, anticipating FDA approval. The company recently sold Zaltenibart for $240 million upfront, bolstering its balance sheet and funding the planned U.S. launch of Narsoplimab.
3 min readImage source: The Motley Fool.Thursday, November 13, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
3 min readU.S. stocks were lower, with the Dow Jones index falling more than 500 points on Friday. Shares of Legence Corp ( NASDAQ:LGN ) rose sharply during Friday's session after delivering mixed third-quarter results in its first earnings report since going public.
4 min readNovo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.
3 min read
